|
CISS
|
TOAST
|
Total
|
|---|
|
LAA
|
CE
|
SAO
|
SOE
|
SUE
|
|---|
|
LAA
|
77
|
2
|
11
|
0
|
52
|
142
|
|
LAA-A
|
0
|
0
|
0
|
0
|
0
|
0
|
|
LAA-1
|
34
|
0
|
3
|
0
|
26
|
63
|
|
LAA-2
|
20
|
1
|
4
|
0
|
17
|
42
|
|
LAA-3
|
4
|
0
|
1
|
0
|
3
|
8
|
|
LAA-4
|
19
|
1
|
3
|
0
|
6
|
29
|
|
CS
|
0
|
13
|
0
|
0
|
0
|
13
|
|
PAD
|
1
|
0
|
109
|
0
|
27
|
137
|
|
OE
|
0
|
0
|
0
|
6
|
0
|
6
|
|
UE
|
1
|
0
|
3
|
0
|
18
|
22
|
|
Total
|
79
|
15
|
123
|
6
|
97
|
320
|
-
CISS Chinese ischemic stroke subclassfication, TOAST trial of Org 10172 in acute stroke treatment, LAA large artery atherosclerosis, LAA-A aortic arch atherosclerosis, LAA-1 parent artery (plaque or thrombus) occluding penetrating artery, LAA-2 artery-to-artery embolism, LAA-3 hypoperfusion/impaired emboli clearance, LAA-4 hypoperfusion/impaired emboli clearance, CS cardiogenic stroke, PAD penetrating artery disease, OE other etiologies, UE undetermined etiology, CE cardioembolism, SAO small-artery occlusion, SOE stroke of other etiologies, SUE stroke of undetermined etiology
-
k = 0.569
